Skip to main content
. 2018 Oct 5;41(12):2669–2701. doi: 10.2337/dci18-0033

Figure 8.

Figure 8

Considering oral therapy in combination with injectable therapies. DKA, diabetic ketoacidosis; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1 RA, glucagon-like peptide 1 receptor agonist; SGLT2i, SGLT2 inhibitor; SU, sulfonylurea.